Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Boehringer-Ingelheim
Company Monitoring Page for Boehringer-Ingelheim
latest headlines for company on cafepharma
Jardiance gets parity with Farxiga in US as FDA clears use in heart failure
Pharmaforum
Wed, 08/18/21 - 11:43 pm
Tags:
Eli Lilly
,
Boehringer Ingelheim
,
FDA
,
diabetes
,
Jardiance
,
heart failure with reduced ejection fraction
The 7-year itch? Boehringer culls $600M cancer pact with CureVac, heaping more woe to the biotech
Fierce Biotech
Mon, 08/16/21 - 12:07 pm
Tags:
CureVac
,
MRNA
,
Boehringer Ingelheim
,
COVID-19
,
vaccines
Boehringer takes alteplase to phase 3 for COVID, but drops antibody
Pharmaforum
Tue, 07/27/21 - 10:26 am
Tags:
Boehringer Ingelheim
,
COVID-19
,
antibodies
,
alteplase
Boehringer Ingelheim latest drugmaker to limit 340B discounts
Beckers Hospital Review
Wed, 07/7/21 - 10:27 pm
Tags:
Boehringer Ingelheim
,
340B
Eli Lilly, Boehringer Ingelheim tout pivotal heart failure win for Jardiance, potentially setting up a Novartis showdown
Endpoints
Tue, 07/6/21 - 10:52 am
Tags:
Eli Lilly
,
Boehringer Ingelheim
,
heart failure
,
clinical trials
,
Jardiance
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance
Pharmaforum
Wed, 06/23/21 - 10:59 am
Tags:
AstraZeneca
,
Farxiga
,
heart failure
,
Boehringer Ingelheim
,
Eli Lilly
,
Jardiance
Boehringer, Lilly and Takeda join matchmaker PharmStars' digital health accelerator
Fierce Pharma
Wed, 06/16/21 - 11:50 am
Tags:
PharmStars
,
digital health
,
accelerators
,
Takeda
,
Eli Lilly
,
Boehringer Ingelheim
ASCO: Boehringer, OSE offer promising glimpse of the immuno-oncology drug at the heart of their $1.4B deal
Fierce Biotech
Fri, 05/21/21 - 11:52 am
Tags:
Boehringer Ingelheim
,
OSE Immunotherapeutics
,
immuno-oncology
,
BI 765063
,
ASCO 2021
The retreat of corporate venture funding?
EP Vantage
Fri, 04/23/21 - 11:02 am
Tags:
funding
,
venture funding
,
venture capital
,
AbbVie
,
Amgen
,
Boehringer Ingelheim
,
Bristol Myers Squibb
,
Eli Lilly
,
GSK
,
JNJ
,
Merck
,
Merck KGaA
,
Pfizer
,
Roche
,
Sanofi
,
Takeda
Boehringer and MD Anderson extend KRAS cancer collaboration
Pharmaforum
Wed, 04/14/21 - 09:39 pm
Tags:
Boehringer Ingelheim
,
MD Anderson
,
KRAS
,
cancer
Boehringer’s big cancer reveal draws near
EP Vantage
Mon, 03/29/21 - 10:27 am
Tags:
Boehringer Ingelheim
,
AACR
,
cancer
,
oncology
,
KRAS
COVID-19 drives Boehringer’s R&D spend to record level in 2020
Pharmaforum
Thu, 03/25/21 - 11:49 am
Tags:
Boehringer Ingelheim
,
R&D
,
COVID-19
Boehringer Ingelheim, Gubra to validate new Peptides for obesity
Pharmaceutical Business Review
Tue, 03/2/21 - 10:47 am
Tags:
Boehringer Ingelheim
,
Gubra
,
peptides
,
obesity
JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies
Fierce Biotech
Tue, 01/12/21 - 11:00 am
Tags:
JPMHC 2021
,
Boehringer Ingelheim
,
Enara Bio
,
dark antigens
,
cancer
,
cancer vaccines
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
Pharmaforum
Tue, 01/12/21 - 10:50 am
Tags:
Boehringer Ingelheim
,
Eli Lilly
,
Jardiance
,
FDA
,
heart failure
,
fast track
Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race
Fierce Biotech
Thu, 12/10/20 - 11:27 am
Tags:
Boehringer Ingelheim
,
NBE Therapeutics
,
M&A
,
Merck
,
antibody-drug conjugate
,
ROR1
Citing toxicity concerns, Boehringer Ingelheim drops short-lived IPF pact — keeping $1B+ in its pocket
Endpoints
Wed, 11/11/20 - 11:07 am
Tags:
Boehringer Ingelheim
,
IPF
,
Bridge Biotherapeutics
,
BBT-877
Boehringer, Yale trial digital tech in heart failure
Pharmaforum
Fri, 10/16/20 - 11:08 am
Tags:
Boehringer Ingelheim
,
Yale
,
digital therapeutics
,
digital health
,
heart failure
Boehringer hopes schizophrenia apps will Click into place
EP Vantage
Tue, 09/15/20 - 10:49 am
Tags:
digital therapeutics
,
Boehringer Ingelheim
,
Click Therapeutics
,
schizophrenia
,
CT-155
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone app
Endpoints
Fri, 09/11/20 - 10:44 am
Tags:
Boehringer Ingelheim
,
digital therapeutics
,
Click Therapeutics
,
mobile apps
,
Novartis
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.